The exon 19 canonical deletion is one of the most common activating mutations in the never smoker lung cancer population, accounting for up to an estimated 25–30% of all EGFR activating mutations in lung cancer and approximately 60% of all exon 19 deletion damage in lung cancer [49, 50, 57–60]. This evidence concerns the gene EGFR and lung carcinoma.